Mondobiotech was a Swiss-based biotechnology company focused on developing human peptides as medicaments for patients affected by rare diseases.
| Company type | Public |
|---|---|
| Industry | Pharmaceutical |
| Founded | 2000 |
| Defunct | 2016 |
| Successor | Relief Therapeutics |
| Headquarters | Stans, Switzerland |
History edit
Mondobiotech was founded in 2000 by Fabio Cavalli and Dorian Bevec.[1] The company listed on the Zurich exchange in 2009.[2] In March 2012, Pharma Times'in exclusive negotiations with Pierrel Research, the contact research division of the Italian company Pierrel.[3]
Research and development edit
Mondobiotech created drugs for rare diseases.
Achievements edit
- Winner of the Swiss Life Sciences Prize 2005.
- Selected Technology Pioneer 2008 by The World Economic Forum.
Notes and references edit
- ^ "Mondobiotech". Archived from the original on 2012-07-20. Retrieved 2012-02-29.
- ^ "Swiss Mondobiotech to list on Zurich exchange". Reuters. August 26, 2009. Retrieved November 5, 2021.
- ^ Mansell, Peter (6 March 2012). "Pierrel in negotiations for mondoBIOTECH merger". Pharma Times. Retrieved 9 March 2015.
See also edit
